Ninety One UK Ltd Has $507.68 Million Stake in Edwards Lifesciences Corporation (NYSE:EW)

Ninety One UK Ltd trimmed its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 2.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,004,417 shares of the medical research company's stock after selling 180,263 shares during the period. Edwards Lifesciences comprises approximately 1.4% of Ninety One UK Ltd's investment portfolio, making the stock its 23rd biggest position. Ninety One UK Ltd owned approximately 1.19% of Edwards Lifesciences worth $507,680,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $26,000. Vega Investment Solutions purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $27,000. Millstone Evans Group LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $29,000. Global X Japan Co. Ltd. lifted its position in shares of Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after acquiring an additional 216 shares in the last quarter. Finally, Tradewinds Capital Management LLC lifted its position in shares of Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after acquiring an additional 205 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Performance

NYSE:EW traded down $0.73 during midday trading on Friday, reaching $78.07. The stock had a trading volume of 3,780,176 shares, compared to its average volume of 5,256,833. Edwards Lifesciences Corporation has a 1-year low of $58.93 and a 1-year high of $92.88. The firm's fifty day simple moving average is $76.30 and its 200-day simple moving average is $73.38. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.45 and a quick ratio of 3.66. The stock has a market capitalization of $45.79 billion, a P/E ratio of 11.15, a PEG ratio of 3.96 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The business had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same period last year, the business posted $0.66 EPS. Edwards Lifesciences's revenue was up 6.2% compared to the same quarter last year. On average, equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on EW. Evercore ISI upped their price target on shares of Edwards Lifesciences from $73.00 to $77.00 and gave the company an "in-line" rating in a research report on Tuesday. Wall Street Zen downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Friday, May 16th. Truist Financial cut their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Citigroup reiterated a "buy" rating and issued a $95.00 target price (up previously from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Finally, Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $80.40.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction on Friday, May 9th. The shares were sold at an average price of $74.40, for a total value of $837,000.00. Following the sale, the chief financial officer directly owned 41,098 shares in the company, valued at $3,057,691.20. This trade represents a 21.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Bernard J. Zovighian sold 5,980 shares of the firm's stock in a transaction on Monday, May 5th. The stock was sold at an average price of $74.91, for a total transaction of $447,961.80. Following the completion of the sale, the chief executive officer owned 58,284 shares in the company, valued at $4,366,054.44. This represents a 9.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 40,348 shares of company stock worth $2,977,683 in the last ninety days. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.